First company launched to discover medicines targeting cell behaviour

A first-of-its-kind therapies company has been launched with the aim of discovering and developing medicines by studying and altering cell behaviours.

Cellarity has been launched by Flagship Pioneering, a life sciences business founded in 2017 in Flagship Labs.

Cellarity has developed a broad platform harnessing single-cell technologies and machine learning to unveil the network state of a given cell, defining the cell’s behaviour.

Its platform digitizes and quantifies cellular behaviours, unravels the network dynamics that govern those behaviours, and generates medicines that can direct them. With the unique ability to discover drugs based on cellular behaviour, Cellarity is dramatically increasing the success rate and speed of drug discovery.

Led by Cellarity’s founding CEO and Flagship Pioneering Partner Avak Kahvejian, and co-founder and Senior Associate Nick Plugis, a team of entrepreneurial scientists leveraged cutting-edge, fit-for-purpose data and novel machine learning algorithms to reveal that individual cells have diverse, connected, and fluid behaviours that drive health and disease.

By understanding the molecular networks that govern these behaviours, the company can rapidly design new medicines to control them. This new paradigm shifts the frame of reference for discovering therapeutics from a single target protein or pathway to one that is simultaneously molecular, cellular, phenotypic, organismal, and clinical.

“To fulfill the Flagship Pioneering vision for Cellarity, we’ve brought together a stellar interdisciplinary team of experts in therapeutics development, network biology, AI, and technology,” says Dr Kahvejian.

The Cellarity leadership team includes Cristina Rondinone, who joins as President and member of the Board of Directors from MedImmune-AstraZeneca, where she was Senior Vice President, Head of Cardiovascular, Renal.

Milind Kamkolkar joins as Chief Digital & Data Office from Sanofi, where hewas chief data officer. While Chad Nusbaum, the founder or Broad Technology Labs, a central development resource for the Broad Institute, joins as Chief Technology Officer.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Related news

Takeda opens R&D cell therapy manufacturing facility

Takeda is expanding its cell therapy manufacturing capabilities with the opening of a new 24,000 sq ft cell therapy manufacturing facility at its R&D...

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...